SSRI Anti-Depressants May Increase Suicide Risk In Adults

New research analysing data
that may have been with withheld by drug companies suggests that the
widely-used anti-depressant known as Seroxat in the UK, increases the
likelihood of suicide.
According to this new analysis
the chances that the risk of suicide is increased by taking Seroxat is 90%.
This is not the sort of probability level that can be ignored.
The results of the studies are
clear enough to understand without the use of statistics. In the placebo group
containing 550 patients, one suicide attempt was made while in the group of 916
patients taking Seroxat, seven suicide attempts were made. No attempts were
These kinds of results are
further blows to the most sophisticated anti-depressants yet developed. A
spokesman for GlaxoSmithKine, the manufacturers of Seroxat, executed the
standard duck and weave:
  • Platitude: “We take the safety
    of all our medicines extremely seriously.”
  • Cast doubt: “At this stage,
    it’s not clear what method the researchers have used to arrive at these
  • Head in sand: “…these conclusions
    in no way reflect the picture that has been built up about the benefits and
    risks of paroxetine in adults…”

Margaret Edwards of Sane
encapsulates the problem more precisely:
“Seventy per cent of those
being treated with the new anti-depressants respond well, and the risks of
suicide from untreated depression must be borne in mind in balancing the risks
and benefits.”
the author
Psychologist, Jeremy Dean, PhD
is the founder and author of PsyBlog. He holds a doctorate in psychology from
University College London and two other advanced degrees in psychology.
He has been writing about
scientific research on PsyBlog since 2004. He is also the author of the book
“Making Habits, Breaking Habits” (Da Capo, 2003) and several ebooks.

Kayode Ojo
Kayode Emmanuel Ojo is the Co-Founder and Managing Director at SHEFFA Limited. He is presently studying Computer Science at the National Open University, Victoria Island, Lagos.